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Background: Levels of precursor proteins of collagen I and III are increased in fibrotic pulmonary diseases. This
study determined whether the expression of precursors of type I and III collagen proteins would be increased in
small and large airways of COPD patients in various stages of the disease reflecting fibrogenesis.
Methods: The levels of precursor proteins of collagen I and III were studied by immunohistochemistry and
quantified by image analysis in lung tissue of 16 non-smokers, 20 smokers with normal lung function, 20 smokers
with stage I-II COPD and 8 ex-smokers with stage IV COPD.
Results: In large airways, the subepithelial layer which was positive for precursor proteins of collagen I and III was
thicker in smokers and in stage I-II COPD compared to non-smokers. Large airways in stage IV COPD showed
reduced expression of precursor protein of collagen I whereas precursor of collagen III was increased. The amount
of precursor protein of collagen III was increased in small airways of smokers and stage I-II COPD but reduced in
stage IV COPD.
Conclusions: Precursor proteins of collagen I and III revealed different expression profiles in large and small
airways in various stages of COPD. Smoking enhanced expression of both precursors in large airways with a
positive correlation with pack-years.
Background
Repeated exposure to cigarette smoke induces persistent
inflammation and oxidative stress in lungs, which leads
to damage of lung parenchyma and airways and a pro-
cess of continuous repair and remodeling [1]. It is not
clear why changes in the peripheral lung of some
patients are predominantly emphysematous with loss of
alveolar attachments, increased alveolar septal wall
thickness [2] and decreased lung elastic recoil, while in
others, thickening of the walls of small airways is the
predominant feature [3,4].
The small airways are the major source of airflow
resistance [5] and thus both emphysematous changes
and small airway obstruction increase small airway resis-
tance. The progression of chronic obstructive pulmonary
disease (COPD) is clearly associated with a thickening of
the airway wall and each of its compartments through a
repair or remodeling process [3]. High resolution
computed tomography (HRCT) analysis of COPD lungs
has revealed that the values of forced expiratory volume
in 1 second (FEV1, %predicted) correlate well with air-
way luminal area and, to a lesser extent, with the degree
of wall thickening [6]. Degradation of airway wall elastin
leads to a significant reduction of the elastin content in
small airways and alveoli, and this change correlates
with airflow limitation [7]. Degraded elastin is later
replaced by other components of the extracellular
matrix. Little is known about the composition of this
newly formed extracellular matrix in the small airway
wall. It has been reported that cigarette smoke activates
airway epithelial cells to release mediators that trigger
fibroblast activity [8]. In mice, long term exposure to
cigarette smoke induced a profibrotic response in the
airways but the parenchyma failed to repair damage to
the matrix [9].
There are clear histopathologic differences between
asthma and COPD [10,11], i.e. asthma is characterized
by epithelial shedding, thickened basement membrane
whereas in COPD one encounters alveolar disruption,
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little is known about the turnover of the extracellular
matrix in COPD.
Collagens are the classical components of the extracel-
lular matrix. In lung tissue, collagen I is the most com-
mon collagen and it confers tensile properties while
collagen III permits multidirectional flexibility, contri-
buting to lung compliance [12]. Collagens are synthe-
tized primarily by fibroblasts as precursor molecules
with the propeptides being cleaved during the process of
secretion of the newly formed collagens. Type I procol-
lagen propeptides have been detected in the lungs of
patients with active fibrosis, and an increased amount of
mRNA coding for type I collagen in the foci of highly
activated fibroblasts [13]. The amino-terminal propep-
tide of type III procollagen (PIIINP) has been claimed to
be a marker of the synthesis of type III collagen since
its concentration was elevated during wound healing
[14]. The levels of PINP and PIIINP have been reported
to be increased in sarcoidosis [15] as well as in the
bronchoalveolar lavage fluid obtained from patients with
interstitial lung diseases [16] and in developing lung
[17].
Cigarette smoke induces changes in lung tissue that
are not simply destructive since the smoke can also trig-
ger an active repair process leading to protein produc-
tion and small airway remodeling. It is not known
whether the destruction of lung parenchyma leads to
the compensatory formation of connective tissue in an
attempt to preserve lung tissue integrity. The aim of this
study was to evaluate the expression of precursor pro-
teins of type I and III collagen in small and large air-
ways of COPD patients in order to determine if
the expression of these proteins would change during
the progression of COPD.
Methods
Lung tissue specimens from 56 patients (20 current
smokers with COPD, 20 current smokers with normal
lung function and 16 life-long non-smokers) undergoing
resection for lung tumour were drawn for immunohisto-
chemical studies from the archives of the Department of
Pathology, Oulu University Hospital. Due to the fact
that the resection of malignant tumors may theoretically
have an influence on the adjacent structures, lung tissue
specimens of non-malignant lung obtained during sur-
gery for hamartomas were additionally included (four in
the non-smoker group, one in the smoker group and
one in the COPD-group). In all, 33% of the operations
were pulmectomies, 60% lobectomies and 7% bilobec-
tomies. No wedge resections were included. Tissue spe-
cimens from tumor-free central bronchi and peripheral
l u n gt i s s u ew e r es e l e c t e d .T h ep a t i e n t sw e r en o t
receiving any corticosteroid therapy (neither inhaled nor
systemic) and did not suffer from an asbestos-related
disease. In addition, lung tissue from 8 patients (4 with
alpha-1-antitrypsin deficiency and 4 with a normal
alpha-1-antitrypsin levels) undergoing lung transplanta-
tion due to very severe i.e. stage IV COPD were
obtained from the Departmento fP a t h o l o g y ,H e l s i n k i
University Central Hospital. These patients were receiv-
ing either inhaled or systemic corticosteroid treatment
and they were all ex-smokers. The lungs were fixed in
inflation. The size of the each lung tissue specimen was
approximately 1-2 cm
2. COPD was defined on the basis
of preoperative lung function: FEV1/FVC less than 70%
and no reversibility (bronchodilatation effect less than
12%). The clinical characteristics were obtained from
the patient records (Table 1).
Immunohistochemistry
Formalin-fixed paraffin-embedded lung tissue specimens
were identified from computerized records. All material
was re-evaluated by a pulmonary pathologist and a pul-
monologist. Two tissue blocks from each patient were
selected, one from the resection line with central carti-
lage-containing bronchus and the other from the
peripheral lung. Four-μm sections were cut for immuno-
histochemical analyses. The sections were deparaffinized
in xylene and rehydrated in a descending ethanol series.
Endogenous peroxidase was blocked by incubating the
sections in 3% hydrogen peroxide in absolute methanol
for 15 minutes.
The primary polyclonal antibodies to the amino-term-
inal propeptides of human type I procollagen (PINP;
0.658 ug/ul) and type III procollagen (PIIINP; 0.15 μg/
μl) were produced as described previously [18,19] and
used at concentrations of 1:10000 and 1:4000, respec-
tively. Antibodies to these amino-terminal propeptides
react intracellularly with the amino-terminal domains of
procollagen molecules that are associated with increased
collagen synthesis, and extracellularly with pN-collagen
in collagen fibres (either mature or preferentially newly
synthesized) in the extracellular space. Serial sections of
additional cases were taken to demonstrate the co-
localization of studied collagen I and III propeptides
and fibroblasts, using antibodies against alpha-smooth
muscle actin (1:1000) and vimentin (1:1500).
The immunohistochemical staining was performed as
previously described [15,17] using the Histostain-Plus
Kit (Zymed Laboratories Inc, San Francisco, CA), and
the chromogen was aminoethyl carbazole (AEC) (Zymed
Laboratories Inc.). In the negative controls, the primary
antibodies were substituted with phosphate-buffered sal-
ine (PBS) or rabbit primary antibody isotype control
from Zymed Laboratories Inc.
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Analyses of small airways
All membranous bronchioles with diameters less than 2
mm were analyzed. Digital photographs were taken
using a Leica DFC 320 camera attached to a Nikon Mik-
rophot SA microscope, via Leica IM 50 software. The
measurements made are shown in Figures 1 and 2:
these included an assessment of the diameter of the
lumen, both longest and shortest dimensions; area and
perimeter of the lumen bounded by respiratory epithe-
lium; area and perimeter surrounded by the basement
membrane and epithelial cell height, measured at 15
random locations. The investigator performing the mor-
phometric airways assessments was blinded to the clini-
cal data. The characteristics of the studied small airways
are described in Table 2.
Precursor proteins of collagen I and III
The immunohistochemical expression of precursor
proteins of collagen I and III was quantified by the
image analysis method. Immunohistochemically stained
slides of central bronchi and peripheral bronchioli were
photographed digitally so as to include all of the chosen
material described in the previous paragraph. The extent
of positive expression was measured in large and small
airways in each study case. The quantification was based
on a measurement of the thickness of the subepithelial
band expressing precursor proteins of collagen I and III
at 30 random locations and the subepithelial area
expressing these precursor proteins between the
Table 1 Patient characteristics of the immunohistochemical samples
Non-smokers n = 16 Smokers n = 20 COPD stage I-II n = 20 COPD stage IV n = 8 p-value
Age, years 65 (13)** 63 (8) 65 (7) 54 (8) 0.039
Sex M:F 8:8 15:5 16:4 5:3 0.096
Pack-years 0* 46 (20) 39 (14) 34 (18) < 0.001
FEV1 l/s 2.96 (1.19)§ 3.02 (0.71) 2.2 (0.54) 0.66 (0.24) < 0.001
FEV1 %predicted 98 (15) 91 (9)# 68 (13) 21 (12) < 0.001
FEV1 postbd 2.98 (1.1) 3.26 (0.81) 2.23 (0.38) NA
FVC 3.44 (1.3) 3.59 (0.91) 3.51 (1.1) 1.78 (1.0) < 0.001
FVC postbd 3.46 (1.21) 3.79 (1.1) 3.66 (1.16) NA
FEV1/FVC % 86 (9)* 84 (11)# 60 (8) 37 (13) < 0.001
DCO %predicted 91 (15)** 77 (15)§§ 75 (10) 29 (8) < 0.001
DCO/VA %predicted 89 (11)** 82 (12)§§ 77 (21) 46 (11) < 0.001
Mean (SD)
*The mean difference between non-smokers and smokers is significant at the 0.05 level, Dunnett t-test.
§ The mean difference between non-smokers and COPD-patients is significant at the 0.05 level, Dunnett t-test.
# The mean difference between smokers and COPD-patients is significant at the 0.05 level, Dunnett t-test.
** The mean difference between non-smokers and patients with severe COPD (GOLD stage IV) is significant at the 0.05 level, Dunnett t-test
§§ The mean difference between smokers and patients with severe COPD (GOLD stage IV) is significant at the 0.05 level, Dunnett t-test
Figure 1 Analysis of small airways by the image analysis
method. Short and long diameter of the bronchioles.
Figure 2 Analysis of small airways by the image analysis
method. Measurements: internal perimeter (blue line), basement
membrane perimeter (green line) and external perimeter of
expression of precursor protein of collagen III (orange line).
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border. Staining was assessed with an image analysis
system using freely available software ImageJ version
1.24o developed at the National Institutes of Health,
using the technique described by Kim et al [20].
Statistical methods
The statistical analyses were performed with SPSS for
Windows software (SPSS, Chicago, IL, USA). Continu-
ous data were compared using analysis of variance
(ANOVA). When ANOVA results indicated that the
groups differed, post hoc comparisons were performed
using two-tailed t-tests. Categorical data were compared
using Fisher’s exact test designed for small sample
groups. P-values less than 0.05 were considered statisti-
cally significant.
Ethical considerations
The study protocol was approved by the ethical commit-
tees of the University of Oulu and Oulu University Hos-
pital, Helsinki University Central Hospital and by the
Finnish Natiolegal Board.
Results
Image analysis of small airways
Peripheral lung samples showed 1-3 transversely cut
bronchioles (diameter < 2 mm) per case. Although
bronchioles of stage IV (very severe) COPD were col-
lapsed with a small internal lumen area, the other
dimensions did not reveal any statistically significant dif-
ferences between the groups (Table 2). The thickness of
the airway wall within the reticular basement membrane
(RBM included) was 23.3 (12.3) μm in the non-smoker
group, 26.1 (9.6) μm in the smoker group, 30.9 (11.1)
μm in the stage I-II (mild to moderate) COPD group
and 22.0 (4.7) μm in the stage IV COPD group, the dif-
ference being statistically significant between the two
COPD groups. There was a negative correlation between
the diffusion coefficient and the thickness of measured
compartment (r = -0.560, p = 0.010) in the COPD
group but no correlations with other lung function
measurements.
Immunohistochemical expression and image analysis
of type I and III collagen protein precursors
Immunohistochemical staining of the precursor pro-
tein of collagen I and III was present mainly extracellu-
larly, being visible as linear and reticular fibers or as
more intensive bands in the subepithelial layer of central
bronchi as well as in the peripheral bronchioles. (Figures
3 and 4). The adventitia of vascular walls and the area
demarcating chondrocytes displayed pronounced immu-
noreactivity. The airway epithelium itself was always
negative. The alveolar epithelium was usually negative
for both precursor proteins, with the exception of some
cases which exhibited intense local positivity within
emphysematic alveolar walls. The overall immunohisto-
chemical expression of precursor protein of collagen III
was more pronounced than that of collagen I.
Precursor protein of collagen I
Only 15% of non-smoking cases exhibited immunoreac-
tivity for the precursor of collagen I in the subepithelial
layer of the central bronchus, compared to 45% of smo-
kers and 52% of COPD-patients (p = 0.031, Pearson’s
Chi-Square). The precursor protein of collagen I positive
subepithelial layer was thicker in the smokers and
patients with stage I-II COPD when compared to the





COPD stage I-II n =
35





Longest 0.89 (0.70) 0.72 (0.36) 0.84 (0.60) 0.70 (0.40) 0.759
Shortest 0.40 (0.50) 0.26 (0.174) 0.30 (0.21) 0.07 (0.03) 0.085
Average 0.64 (0.54) 0.49 (0.24) 0.48 (0.27) 0.40 (0.21) 0.503
Internal lumen
perimeter, mm 3.17 (2.14) 2.60 (1.45) 2.48 (1.25) 2.17 (1.04) 0.587
Area, mm
2 0.45 (0.85) 0.17 (0.16) 0.26 (0.28) 0.09 (0.14) 0.248
Basement membrane
Perimeter, mm 3.30 (2.25) 2.72 (1.46) 2.47 (1.22) 2.34 (1.11) 0.591
Area, mm
2 0.56 (0.93) 0.26 (0.21) 0.29 (0.30) 0.17 (0.17) 0.239
Epithelial area, mm
2 0.11 (0.10) 0.09 (0.08) 0.09 (0.09) 0.08 (0.06) 0.938
Thickness of airway wall within RBM**
(μm)
23.3 (12.3) 26.1 (9.6) 30.9 (11.1) 22.0 (4.7) 0.029
mean (SD)
n = number of bronchioli studied
*statistically significant difference compared to stage IV COPD
**RBM = reticular basement membrane, including the membrane itself
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diminished expression of collagen I precursor when
compared with the patients with milder disease or the
smokers (Figure 5). The difference between stage I-II
and stage IV COPD was statistically significant. Smokers
expressing positivity for precursor of collagen I in the
large airways had less airway obstruction than the cases
with negative expression (FEV1% predicted 79% vs 66%,
p = 0.045; MEF50% predicted 65% vs 43%, p = 0.014).
The subepithelial layer of bronchi expressing precursor
protein I was thicker in smokers compared to the
corresponding situation in non-smokers (2.74 μmv s
0.95 μm, p = 0.049). In smokers, the correlation between
the positive layer thickness and pack years was weakly
positive (r = 0.255, p = 0.039). No correlation was found
between the lung functions and the expression of pre-
cursor protein of collagen I in the subepithelial layer.
The subepithelial layer of small bronchioles did not
exhibit any positivity for the precursor protein of
collagen I.
Precursor protein of collagen III
The subepithelial layer of large airways expressing pre-
cursor protein of collagen III was thicker in smokers
than in non-smokers, the exact measures being 14.97
μm vs 10.82 μm,(p = 0.019). (Figure 6) The subepithelial
layer thickness displayed a positive correlation with
pack-years in healthy smokers (r = 0.519, p = 0.016) as
well as in COPD-smokers (r = 0.346, p = 0.007). In
addition, the patients with stage IV COPD displayed
increased expression of precursor protein of collagen III
in their large airways. In bronchioles i.e. in small air-
ways, the staining of precursor protein of collagen III
was increased in the smokers and in these cases the
thickness of the subepithelial layer expressing precursor
of collagen III protein correlated positively with pack-
years (r = 0.319, p = 0.024). In the patients with COPD,
the amount of precursor protein of collagen III corre-
lated with pack-years (r = 0.497, p = 0.022), FEV% pre-
dicted (r = 0.549, p = 0.010) and DCO/VA (r = 0.471, p
= 0.042). The COPD-patients in stage I-II displayed
increased expression of collagen III precursor protein in
their small airways, but this was declined in the patients
AB
CD
Figure 3 Immunohistochemical staining for precursor protein
of collagen III in bronchus of a non-smoker (A), a smoker (B), a
patient with mild (stage I) COPD (C) and a patient with very
severe (stage IV) COPD (D) showing that in large airways, the
subepithelial layer that was positive for precursor protein of
collagen III was thicker in smokers and in stage I-II COPD
compared to non-smokers and patients with stage IV COPD.
Figure 4 Immunohistochemical staining for precursor protein
of collagen III in small airways of a non-smoker (A), a smoker
(B), a patient with stage I COPD (C) and a patient with stage IV
COPD (D). showing increased expression of precursor protein of
collagen III in small airways of smokers and stage I-II COPD, and
decreased expression in stage IV COPD.
Figure 5 Precursor protein of collagen I in the large airways of
non-smokers, smokers and the patients with COPD. Thickness of
subepithelial layer expressing precursor protein of collagen I
displayed an increase of this protein in smokers and in patients with
stage I-II COPD compared to non-smokers. Its thickness was highly
diminished in the patients with very severe COPD. The difference
between stage I-II and stage IV COPD was statistically significant.
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precursor protein of collagen III expressing subepithelial
layer thicknesses in bronchioles were 6.51 μmi nn o n -
smokers, 6.87 μmi ns m o k e rg r o u p ,8 . 4 9μmi nt h e
patients with stage I-II COPD and 2.87 μmi nt h e
patients with stage IV COPD. The difference between
stage I-II and stage IV COPD groups was significant at
the 0.05 level. The subepithelial area with positive col-
lagen III precursor staining was smaller in patients with
s t a g eI VC O P Da sc o m p a r e dt on o n - s m o k e r s( p=
0.017), smokers (p = 0.045) and those patients with
stage I-II COPD (p = 0.012) (Figure 8).
The co-localization study
The expression of propeptides for collagen I and III was
found to co-localise with spindle-shaped, alpha-smooth
muscle actin positive, vimentin negative fibroblastic cells
in small airways (Figure 9) and large airways (Figure 10).
Discussion
This is the first study to investigate the immunohisto-
chemical expression of precursor proteins of collagens I
and III as quantified by an image analysis technique in
non-smokers, smokers and patients with COPD at
Figure 6 Precursor protein of collagen III in the large airways
of non-smokers, smokers and the patients with COPD. The
subepithelial layer expressing precursor protein of collagen III was
thicker in all smoker groups compared to non-smokers.
Figure 7 Precursor protein of collagen III in the small airways
of non-smokers, smokers and the patients with COPD. The
subepithelial layer expressing precursor protein of collagen III was
thicker in smokers and in the patients with stage I-II COPD
compared to the non-smokers but its accumulation was decreased
in patients with stage IV COPD. The difference between stage I-II
and stage IV COPD was statistically significant (p = 0.015).
Figure 8 Precursor protein of collagen III in the small airways
of non-smokers, smokers and the patients with COPD. The
subepithelial area with positive staining for precursor protein of
collagen III was thinner in severe COPD compared to non-smokers
(p = 0.017), smokers (p = 0.045) and patients with stage I-II COPD (p
= 0.012).
Figure 9 Spindle-shaped, alpha-smooth muscle actin positive
fibroblastic cells were found to co-localise with collagen III
propeptides in serial sections of peripheral bronchioli. Almost
no expression of procollagen I was seen (A-D), with variable
expression of collagen III propeptide (E-H) and co-localization of
spindle-shaped alpha-smooth muscle actin positive fibroblastic cells
(I-L, arrows), with immunohistochemistry for vimentin (M-P, M with
negative PBS-control).
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were increased in large airways of smokers and patients
with stage I-II COPD. In contrast, precursor proteins
were expressed differently in large airways of patients
with stage IV COPD i.e. in these patients the amount of
precursor protein of collagen I was reduced whereas
that of collagen III was elevated. The present study also
revealed that the increase of the precursor protein of
collagen I and III in the large airways of smokers corre-
lated positively with pack-years. No detectable expres-
sion of the precursor protein of collagen I was found in
small airways, whereas the amount of the precursor pro-
tein of collagen III was increased in the bronchioles of
smokers and in stage I-II COPD. Overall, the amounts
of precursors of collagen I and III were increased in
smokers and stage I-II COPD but tended to decline
either in large or small airways in stage IV COPD.
The accumulation of the precursor protein of collagen
I could represent the synthesis of type I collagen which
in turn offers protection from the distension and shear-
ing effects of hyperinflation, while its absence may
further contribute to alveolar wall disruption and
emphysema formation in conjunction with other
mechanisms. In contrast, the expression of the precur-
sor protein of collagen III within small airways was
increased in patients at stages I-II COPD and moreover,
its amount correlated positively with the results of the
lung function tests. The very thin subepithelial layer
expressing collagen III precursor proteins in stage IV
COPD may be attributable to decreased fibrotic activity
in small airways in end-state COPD, and the combina-
tion of this defective repair of injured airways with elas-
tin destruction which could evoke diminished
compliance and disrupt the elastic properties of lung
tissue. Decreased precursor protein of collagen III in
stage IV COPD may also be due to the end-stage of the
remodelling process, a diminished capacity of the lung
cells to produce collagen III, and/or a shift in the bal-
ance towards degradation. The discrepancy in the
expression profiles of the precursor proteins of col-
lagens I and III reflects the fact that the regulative pro-
cesses of these two collagens differ in COPD. In
addition, there were few spindle shaped alpha-smooth
muscle actin positive fibroblastic cells especially in the
small airways but these cells co-localised with the
expression of the studied collagen propeptides, suggest-
ing that fibroblasts could well be one source of this
newly synthesised collagen.
We have previously shown that in the developing
human lung, the precursor proteins of collagen I and III
were expressed through all gestational ages and also in
respiratory distress syndrome and bronchopulmonary
dysplasia in a rather similar way both in bronchi and in
the bronchioles underneath the airway epithelium [17]
T h u s ,f i n d i n gad i f f e r e n c eb e t w e e nt h ee x p r e s s i o no f
precursor I and III in the small airways of patients with
COPD was somewhat surprising. This may indicate that
there is a different kind of fibrotic process in COPD
compared to that occurring in other fibrotic lung dis-
eases. Furthermore, we have investigated the expression
of the precursors of collagens I and III in idiopathic pul-
monary fibrosis (IPF)/usual interstitial pneumonia (UIP);
in that disease, precursor protein of type I was mostly
present as intracellular spots in the newly formed fibro-
sis while the precursor protein of type III was expressed
underneath the metaplastic alveolar epithelium [15]. In
general, mRNAs of both collagens have colocalized with
the precursor proteins [13,17]. The most abundant cell
type displaying positivity for mRNAs seemed to be the
myofibroblast. One could speculate that different subpo-
pulations or phenotypes of fibroblasts are involved in
the fibrogenesis in different lung disorders.
The collagen III deposition which was accompanied by
an excess of fibroblasts as detected in the large airways
of patients with severe asthma was not observed in
COPD [21]. The myofibroblasts which are often seen in
asthma with subepithelial fibrosis [22], have not been
studied in COPD. The exact producer of this remodeled
matrix as well as the role of inflammatory cells and acti-
vated epithelium in the remodeling process and in fibro-
blast activation/differentiation into myofibroblasts in
small airway fibrosis in COPD is unclear. Fibroblasts
from COPD-patients are known to have a reduced cap-
ability to repair injured tissue [23]. In addition, it is not
Figure 10 Spindle-shaped, alpha-smooth muscle actin positive
fibroblastic cells were found to co-localise with collagen III
propeptides in serial sections of central bronchi. Almost no
expression of collagen I propeptides was seen (A-D), but there was
variable expression of collagen III propeptide (E-H) and co-
localization of spindle-shaped alpha-smooth muscle actin positive
fibroblastic cells (I-L, arrows), with immunohistochemistry for
vimentin (M-P, P with negative anti-rabbit-control).
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the tissue and are responsible for fibrosis via increased
matrix synthesis and contraction of the tissue, as is the
case in fibrotic lung disorders [24]. Equally it is unclear
if the peribronchial excess in connective tissue repre-
sents a disordered non-functional regional response to
inflammation and oxidative stress or whether the small
airway fibrosis is a compensatory phenomenon to the
increased collapsibility secondary to the loss of alveolar
attachments.
In our earlier studies, we found diminished levels of
the rate-limiting enzyme of glutathione synthesis in
smokers’ lung [25] and this probably contributes to the
progression of lung injury. The levels of some antioxi-
dant enzymes are known to be increased in the airways
of smokers [26], reflecting the complexity of the oxi-
dant-antioxidant balance in the pathogenesis of COPD.
The oxidant-antioxidant imbalance in turn has multiple
effects on the levels and activation of growth factors.
Under in vitro conditions cigarette smoke can inhibit
fibroblast recruitment, proliferation and extracellular
matrix contraction [27] as well as evoking reversible
DNA damage [28]. The density of fibroblasts has been
shown to be critical for TGFb activation by cigarette
smoke [29]. It has been reported that cigarette smoke
releases active TGFb1 from tracheal explants without
the need for exogenous inflammatory cells and causes
upregulation of connective tissue growth factor and
upregulation of procollagen gene expression [30].
The limitations to this study include the lack of stage
III COPD patients, since they have advanced airflow
obstruction and operative treatment for their lung
tumors is often not possible. Patients in the stage IV
COPD groups were younger than those in the other
groups, they were ex-smokers and they were heavily
medicated often with both inhaled and systemic corti-
costeroids. Half of the patients with stage IV COPD had
alpha-1-antitrypsin deficiency while the other half had
normal levels of alpha-1-antitrypsin; however the histo-
pathological destruction of lung tissue showed no differ-
ence between these two groups. In addition, no age-
related change in the collagen content of the lungs of
non-smokers has been found [31]. Little is known about
the antifibrotic effect of steroids in COPD or the effect
of smoking cessation on fibrogenesis in COPD. Cigarette
smoke inhibits TGFb release from airway epithelial cells
[32] and in COPD an aberrant responsiveness of fibro-
blasts to cigarette smoke extract has been reported [33]
but the net effect on fibrogenesis is unclear. Since the
nature of this study is retrospective, and proper quantifi-
cation of histological changes would require a multilevel
sampling design, the problem of selection bias cannot
be excluded. Thus, studies with measurement of a refer-
ence volume of entire lung and a random sampling
design will be needed to confirm our results. Further
studies will be needed to investigate these proteins in
various subtypes of COPD i.e. airway or emphysema
predominant disease. The number of peripheral bronch-
ioli was low in stage IV COPD. This finding is new and
could even be related to the progression of COPD.
Procollagen I and III are not specific to any fibrotic
disease, since these proteins are components of both
normal and enhanced remodeling. Our study confirms
earlier reports in COPD patients that there is actual
fibrosis beneath the basement membrane with increased
collagen accumulation [34]. The differences between
large and small airways confirm previous findings that
remodeling changes are present also in the large airways
[35], and moreover, this phenomenon is present in the
large airways before the obstruction has developed. The
pathogenetic changes noted in the small airways of
COPD may represent local wound healing of injured
epithelium rather than a disease of uncontrolled fibrosis
of the airways.
We conclude that smoking induces immunohisto-
chemical expression of precursor proteins of collagen I
and III in large airways of healthy and diseased lung and
this change correlates with the pack-years. Moreover the
amounts of both precursors exhibit variable expression
profiles in large and small airways of patients with
COPD in various stages of the disease. Accumulation of
precursor protein of collagen III is increased in the
small airways of patients with mild-moderate COPD but
declines in end-state disease, possibly as a marker of the
cessation of active fibrogenesis or as a result of
enhanced degradation of the protein. These results sug-
gest that smoking can induce the fibrogenesis of airways
even in ‘healthy’ smokers with normal lung function.
Furthermore, in COPD not only the small airways, but
also the large airways display evidence of fibrogenesis.
The effective treatment of the small airway disease in
COPD will require a better understanding of the rela-
tionship between airway fibrosis and airflow obstruction,
and also an awareness of extracellular matrix turnover
and its regulation in smoking related diseases.
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